News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
IMAAVY Shows Durable Haemoglobin Response in Phase 2/3 Study for Warm Autoimmune Haemolytic Anaemia
Thursday, June 11, 2026Johnson Johnson has reported positive results from the Phase ENERGY study showing that IMAAVY nipocalimabaahu achieved a statistically significant and durable haemoglobin response in patients with warm
PharmaEssentia Receives Taiwan Approval for BESREMi in Essential Thrombocythaemia
Thursday, June 11, 2026PharmaEssentia has received approval from Taiwans Ministry of Health and Welfare MOHW for BESREMi ropeginterferon alfabnjft to treat adult patients with essential thrombocythaemia ET
FloBiotech Signs Agreement with UCLA Health to Advance Neurodegenerative Disease Treatments
Wednesday, June 10, 2026FloBiotech has entered into an agreement with UCLA Health to support the development of a new class of therapies for neurodegenerative diseases by targeting protective biological pathways involved in disease progression
FDA Expands Approval of Pfizer’s HYMPAVZI for Additional Hemophilia A and B Patient Groups
Tuesday, June 09, 2026Pfizer has received approval from the US Food and Drug Administration FDA for an expanded indication of HYMPAVZI marstacimabhncq extending its use to patients aged years and older with hemophilia
Engitix and GSK Partner to Advance New Targets for Liver Fibrosis Treatment
Tuesday, June 09, 2026Engitix has entered into a strategic research collaboration and option agreement with GSK to identify and validate novel therapeutic targets aimed at promoting liver fibrosis regression
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Friday, June 05, 2026Biogen has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy Designation to salanersen for the treatment of spinal muscular atrophy SMA
Teva launches AHZANTIVE biosimilar to Eylea across Europe
Friday, June 05, 2026Teva Pharmaceutical Industries has launched AHZANTIVE aflibercept a biosimilar to Eylea in Europe expanding its biosimilars portfolio and strengthening its presence in the ophthalmology sector
Lundbeck Partners with Cradle to Advance AI-Driven Brain Disorder Treatments
Thursday, June 04, 2026H Lundbeck AS has entered a partnership with Cradle to support the discovery and optimisation of biotherapeutics for brain disorders using artificial intelligence
Lupin and Natco Receive US FDA Approval for Eribulin Mesylate Injection
Wednesday, June 03, 2026Lupin Limited and its alliance partner Natco Pharma have received approval from the US Food and Drug Administration FDA for Natcos Abbreviated New Drug Application ANDA for Eribulin Mesylate Injection mg mL
Vertex Receives FDA Acceptance for Povetacicept Application in IgA Nephropathy
Tuesday, June 02, 2026Vertex Pharmaceuticals has announced that the US Food and Drug Administration FDA has accepted its Biologics License Application BLA for povetacicept an investigational treatment for adults with immunoglobulin A nephropathy IgAN
